JP2022524759A5 - - Google Patents
Info
- Publication number
- JP2022524759A5 JP2022524759A5 JP2021553031A JP2021553031A JP2022524759A5 JP 2022524759 A5 JP2022524759 A5 JP 2022524759A5 JP 2021553031 A JP2021553031 A JP 2021553031A JP 2021553031 A JP2021553031 A JP 2021553031A JP 2022524759 A5 JP2022524759 A5 JP 2022524759A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- dichlorophenyl
- carboxamide
- pyrimidine
- methylpyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19161323 | 2019-03-07 | ||
| EP19161323.1 | 2019-03-07 | ||
| US201962879597P | 2019-07-29 | 2019-07-29 | |
| US62/879,597 | 2019-07-29 | ||
| PCT/US2020/021726 WO2020181283A1 (en) | 2019-03-07 | 2020-03-09 | Carboxamide-pyrimidine derivatives as shp2 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524759A JP2022524759A (ja) | 2022-05-10 |
| JP2022524759A5 true JP2022524759A5 (cg-RX-API-DMAC7.html) | 2023-03-15 |
| JP7734586B2 JP7734586B2 (ja) | 2025-09-05 |
Family
ID=70057354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553031A Active JP7734586B2 (ja) | 2019-03-07 | 2020-03-09 | Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11033547B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3935049A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7734586B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113795483B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020232026B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3127361A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286077A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020181283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| CN115916765B (zh) * | 2020-07-10 | 2025-04-18 | 浙江海正药业股份有限公司 | 吡啶或嘧啶类衍生物及其制备方法和用途 |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114181159B (zh) * | 2021-12-28 | 2024-02-20 | 南通大学 | 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN116332908B (zh) * | 2023-03-21 | 2024-07-02 | 杭州医学院 | 一种shp2变构抑制剂及其制备方法和应用 |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121219286A (zh) * | 2023-05-25 | 2025-12-26 | 正大天晴药业集团股份有限公司 | 含有酰胺取代的芳香环的化合物、其药物组合物及用途 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120842203B (zh) * | 2025-09-24 | 2025-12-05 | 山东大学 | 特异性检测shp2的近红外荧光探针的制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| ES2699351T3 (es) * | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2016120355A2 (en) * | 2015-01-30 | 2016-08-04 | Basf Se | Herbicidal phenylpyrimidines |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| IL311645B2 (en) * | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| EP3490985B1 (en) * | 2016-07-26 | 2020-08-05 | Basf Se | Herbicidal pyrimidine compounds |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| JP7447002B2 (ja) * | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤 |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| NL2019805B1 (en) | 2017-10-26 | 2019-05-06 | Swedish Match Lighters Bv | A child resistant gas lighter |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| WO2019121373A1 (en) * | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| CN117263942A (zh) | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| WO2020058062A1 (de) * | 2018-09-19 | 2020-03-26 | Bayer Aktiengesellschaft | Herbizid wirksame substituierte phenylpyrimidinhydrazide |
| TW202028183A (zh) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| CN114761394B (zh) * | 2020-01-16 | 2024-03-29 | 浙江海正药业股份有限公司 | 吡啶或嘧啶类衍生物及其制备方法和用途 |
| CN115916765B (zh) * | 2020-07-10 | 2025-04-18 | 浙江海正药业股份有限公司 | 吡啶或嘧啶类衍生物及其制备方法和用途 |
-
2020
- 2020-03-09 US US16/813,192 patent/US11033547B2/en active Active
- 2020-03-09 EP EP20715647.2A patent/EP3935049A1/en active Pending
- 2020-03-09 CA CA3127361A patent/CA3127361A1/en active Pending
- 2020-03-09 CN CN202080033849.2A patent/CN113795483B/zh active Active
- 2020-03-09 AU AU2020232026A patent/AU2020232026B2/en active Active
- 2020-03-09 JP JP2021553031A patent/JP7734586B2/ja active Active
- 2020-03-09 WO PCT/US2020/021726 patent/WO2020181283A1/en not_active Ceased
-
2021
- 2021-04-30 US US17/245,423 patent/US11696916B2/en active Active
- 2021-09-02 IL IL286077A patent/IL286077A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201413B9 (en) | Fused ring compounds | |
| AU2022246416C1 (en) | Inhibitors of cyclin-dependent kinase 7 (CDK7) | |
| TWI846855B (zh) | 作為shp2拮抗劑的嘧啶酮衍生物 | |
| AU2020232026B2 (en) | Carboxamide-pyrimidine derivatives as shp2 antagonists | |
| JP6655052B2 (ja) | ビヘテロアリール化合物及びその使用 | |
| KR102483020B1 (ko) | Tam 저해제로서의 피롤로트리아진 화합물 | |
| KR101546167B1 (ko) | 브루톤 티로신 키나아제의 억제제 | |
| AU2015323572B2 (en) | Novel compounds | |
| CA3226206A1 (en) | Shp2 inhibitor and use thereof | |
| AU2018239542A1 (en) | Novel heterocyclic derivatives useful as SHP2 inhibitors | |
| SG10202105964RA (en) | Hpk1 inhibitors and methods of using same | |
| BR122020006707B1 (pt) | composto, composição farmacêutica, e, usos dos mesmos | |
| JP2026071405A (ja) | 医薬化合物 | |
| JP2024009891A (ja) | T型カルシウムチャネル阻害剤 | |
| WO2022170043A1 (en) | Quinazoline derived compounds as egfr inhibitors and their uses thereof | |
| JP7681116B6 (ja) | カルボニル置換ジアザスピロ化合物及びその使用 | |
| CA3257448A1 (en) | WEE1 DEGRADATION COMPOUNDS AND THEIR USES | |
| AU2019363657B2 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| WO2020203610A1 (ja) | 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用 | |
| CA3245810A1 (en) | PYRIDO[3,2-D]PYRIMIDINS USED AS HPK1 INHIBITORS | |
| RU2815003C2 (ru) | Гетероциклическое соединение |